SIETES :: 93212 citas

Resultados de la búsqueda por AMIKACINA REFINAR BÚSQUEDA

1.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]

2.

Cox E, Laessig K. FDA approval of bedaquiline - The benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014;371:689-91. [Ref.ID 97889]

3.

Anónimo. Acide para-aminosalicylique. Prescrire 2014;34:340-1. [Ref.ID 97559]

4.

Anónimo. Bédaquiline. Prescrire 2014;34:337-40. [Ref.ID 97558]

5.

Vodovar D, LeBeller C, Mégarbane B, Lillo-Le-Louet A, Hanslik T. Drug fever: a descriptive cohort study from the French National Pharmacovigilance Database. Drug Saf 2012;35:759-67. [Ref.ID 93643]

6.

Bourguignon L, Goutelle S, Gérard C, Guillermet A, Burdin de Saint Martin J, Maire P, Ducher M. Pharmacocinétique de l'amikacine chez l'adulte: une hétérogénéité qui remet en cause le calcul de la dose basé sur le poids. Therapie 2009;64:47-53. [Ref.ID 86030]

7.

Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007;356:656-9. [Ref.ID 79202]

8.

Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;367:633-4. [Ref.ID 76242]

9.

Allegaert K, Anderson BJ, Cossey V, Holford NHG. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006;61:39-48. [Ref.ID 76102]

10.

Hernández ME, Ramos MJ, Ferrer NF. Azlocilina y amikacina: ¿una alternativa terapéutica para la septicemia por estafilococos resistentes?. Rev Panam Salud Publica 2005;16:315-9. [Ref.ID 74445]

11.

Mukherjee JS, Rich M L, Socci AR, Joseph JK, Virú F A, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, Bayona J, Farmer P, Fawzi MCS, Seung KJ. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-81. [Ref.ID 69082]

12.

Friedden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-99. [Ref.ID 67425]

13.

Holdsworth MT, Hanrahan J, Albanese B, Frost J. Outpatient management of febrile neutropenia in children with cancer. Pediatr Drugs 2003;5:443-55. [Ref.ID 66893]

14.

Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, Clairicia M, Barthe J, Delaunay JP, Brousse V, Lenoir G. Nebulized antibiotics in cystic fibrosis. Pediatr Drugs 2002;4:455-67. [Ref.ID 62722]

15.

Farmer P. The major infectious diseases in the world - to treat or not to treat?. N Engl J Med 2001;345:208-10. [Ref.ID 60564]

16.

Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001;345:189-200. [Ref.ID 60562]

17.

Tahaoglu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Özmen I, Kapakli N. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001;345:170-4. [Ref.ID 60561]

18.

Ducher M, Maire P, Cerutti C, Bourhis Y, Foltz F, Sorensen P, Jelliffe R, Fauvel JP. Renal elimination of amikacin and the aging process. Clin Pharmacokinet 2001;40:947-53. [Ref.ID 60392]

19.

Biering-Sorensen F, Bagi P, Hoiby N. Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs 2001;61:1275-87. [Ref.ID 57939]

20.

Lugo-Goytia G, Castañeda-Hernández G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000;34:1389-94. [Ref.ID 54237]